For laboratory research use only. Not for human or veterinary use. Read our research-use policy

Comparison

TB-500 vs thymosin beta-4: fragment or full protein?

The two names are often used as if they were interchangeable. They are not: one is a 43-residue protein and the other, as usually described, is a 7-residue piece of it. Here is what the papers say about each, and how to tell which one is in a vial.

Published 18 November 2026 · Last updated 18 November 2026

At a glance

Thymosin beta-4 and the TB-500 fragment compared
Thymosin beta-4TB-500 (as usually described)
What it isA naturally occurring protein, the major actin-sequestering molecule in eukaryotic cellsA supplier name for a synthetic peptide related to thymosin beta-4
Length43 amino acids7 amino acids
SequenceAc-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES (N-terminally acetylated)Ac-LKKTETQ (residues 17 to 23)
Formula (PubChem)C212H350N56O78S, about 4963 g/molC38H68N10O14, about 889 g/mol
Monoisotopic mass from the formula4960.49 Da888.49 Da; [M+H]+ 889.50
Contains the actin-binding motifYesYes (this is the motif)
Contains Ac-SDKP (residues 1 to 4)YesNo

Where the fragment comes from

Thymosin beta-4 is a 43-residue protein that sequesters monomeric G-actin in a 1:1 ratio (Hannappel and Wartenberg, 1993; Goldstein et al., 2005; Hannappel, 2007). Sosne et al. (2010) review short sequences within the protein that have been linked to particular activities in cell and tissue models: the N-terminal Ac-SDKP, a 15-residue N-terminal site that includes it, and a short sequence containing LKKTETQ, the central actin-binding region, which they associate with cell migration, angiogenesis and wound-healing models. The numbering on this page follows the sequence above: Leu17 to Gln23 is LKKTETQ.

What a vial labelled TB-500 contains

TB-500 is not a standardised chemical name. Esposito et al. (2012) describe finding the N-terminally acetylated 17-23 fragment, Ac-LKKTETQ, in a product named TB-500 by HPLC with high-resolution mass spectrometry, and synthesising it by solid-phase peptide synthesis as a reference. That is the source of the usual description of TB-500 as a fragment. A vial sold under the name may therefore hold either molecule, which is why identity should be verified by mass, not by name. For a fragment of about 889 g/mol and the full protein at about 4963 g/mol the two are unmistakable by mass spectrometry: expect [M+H]+ near 889.50 for the fragment, and a charge-state series from the 4+ ion upward (about 1241.9, 993.7, 828.3) for the full protein.

What the fragment studies show

  • Actin sequestering needs more than the central motif. In a DNase I inhibition assay, thymosin beta-4 sequestered G-actin 1:1, while fragments 13-43 and 24-43 did not inhibit polymerisation. The authors conclude that structural features before position 13 are needed for that function (Hannappel and Wartenberg, 1993).
  • Metabolism of the fragment. Rahaman et al. (2024) quantified Ac-LKKTETQ and its metabolites in vitro and in rats by UHPLC-Orbitrap MS/MS. They report Ac-LK as the main early metabolite and Ac-LKK as a longer-lived one detected up to 72 hours, no cytotoxicity of the parent or metabolites, and, among the compounds tested in a fibroblast scratch assay, a significant effect only for the metabolite Ac-LKKTE. They suggest that wound-healing activity previously attributed to TB-500 may be due to a metabolite rather than the parent form.

Together these papers say that results obtained with full-length thymosin beta-4 cannot be assumed for the fragment, or the other way round. A study should state which molecule, its sequence and its supplier's mass-spectrometry data.

How to check which one you have

  1. Read the mass-spectrometry section of the batch COA and compare the reported m/z or deconvoluted mass with the table above. This guide shows how to compute the expected ions.
  2. Check that the COA gives the sequence or the name of the molecule, not only "TB-500".
  3. For the fragment, confirm the N-terminal acetyl group: the acetylated form is 42.01 Da heavier than the free peptide (Ac-LKKTETQ 888.49 Da vs LKKTETQ 846.48 Da).

Catalog and related pages

Related

References

  1. Hannappel E, Wartenberg F (1993). Actin-sequestering ability of thymosin beta 4, thymosin beta 4 fragments, and thymosin beta 4-like peptides as assessed by the DNase I inhibition assay. Biol Chem Hoppe Seyler 374:117-22. PubMed 8471179 · DOI
  2. Sosne G, Qiu P, Goldstein AL, et al. (2010). Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J 24:2144-51. PubMed 20179146 · DOI
  3. Esposito S, Deventer K, Goeman J, et al. (2012). Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal 4:733-8. PubMed 22962027 · DOI
  4. Rahaman KA, Muresan AR, Min H, et al. (2024). Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B Analyt Technol Biomed Life Sci 1235:124033. PubMed 38382158 · DOI
  5. Goldstein AL, Hannappel E, Kleinman HK (2005). Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med 11:421-9. PubMed 16099219 · DOI
  6. Hannappel E (2007). beta-Thymosins. Ann N Y Acad Sci 1112:21-37. PubMed 17468232 · DOI
  7. Sosne G, Qiu P, Kurpakus-Wheater M (2007). Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent. Clin Ophthalmol 1:201-7. PubMed 19668473

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-amino-acid protein (about 4963 g/mol). TB-500 is a supplier name that is commonly used for the 7-residue fragment Ac-LKKTETQ (about 889 g/mol), which corresponds to residues 17 to 23 of thymosin beta-4. Because the name is not standardised, the mass on a batch COA is what settles which one a vial contains.

Has Ac-LKKTETQ been found in products sold as TB-500?

Yes. Esposito et al. (2012) report detecting and identifying Ac-LKKTETQ in a TB-500 product using HPLC and high-resolution mass spectrometry, and synthesised it by solid-phase peptide synthesis to confirm the identification.

Which part of thymosin beta-4 binds actin?

The central region around residues 17 to 23 (LKKTETQ) is described as the actin-binding domain. Hannappel and Wartenberg (1993) also found that fragments 13-43 and 24-43 did not inhibit actin polymerisation, so sequence before position 13 matters for the full actin-sequestering function.